Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland, January to February 2020
Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland, January to February 2020
复制标题
DOI：
10.2807/1560-7917.es.2020.25.11.2000266
复制
发表时间：
2020-03-19
期刊：
影响因子：
19
通讯作者：
Savolainen-Kopra, Carita
中科院分区：
文献类型：
--
作者：
Haveri, Anu;Smura, Teemu;Savolainen-Kopra, Carita
芬兰于二零二零年一月二十九日确诊首例冠状病毒病（COVID-19）。未发现继发病例。我们描述的临床图片和实验室检查结果3-23天以来的第一个症状。分离到SARS-CoV-2/Finland/1/2020毒株，其基因组显示与来自武汉的参考株的单核苷酸取代。中和抗体应答在9天内出现，沿着特异性IgM和IgG应答，尤其靶向核衣壳和刺突蛋白。
The first case of coronavirus disease (COVID-19) in Finland was confirmed on 29 January 2020. No secondary cases were detected. We describe the clinical picture and laboratory findings 3-23 days since the first symptoms. The SARS-CoV-2/Finland/1/2020 virus strain was isolated, the genome showing a single nucleotide substitution to the reference strain from Wuhan. Neutralising antibody response appeared within 9 days along with specific IgM and IgG response, targeting particularly nucleocapsid and spike proteins.